How to improve predictions and outcomes of recurrent prostate cancer

Poster Session 46

Sunday 17 March
14:00 - 15:30

Location: Green Area, Room 10

Chairs: G. De Meerleer, Ghent (BE)
G. Gandaglia, Milan (IT)
A. Mendoza-Valdes, Mexico City (MX)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

Prospective randomized trial of gene expression classifier utility in men at high risk of recurrence following radical prostatectomy (G-MINOR)

By: Morgan T. 1, Okoth L. 1, Feng F. 2, Johnson A. 1, Lane B. 3, Linsell S. 1, Khurdish G. 1, Montie J. 1, Fishbane N. 4, Marti T. 5, Du Plessis M. 6, Mehr R. 7, Davicioni E. 8, Maatman T. 9, Wojno K. 10, Burks F. 11, Rodriguez P. 12, Liu N. 13, Sarle R. 14, Miller D. 1, Cher M. 15

1University of Michigan, Michigan Medicine, Dept. of Urology, Ann Arbor, United States of America,
2University of California, Dept. of Radiation Oncology, San Francisco, United States of America,
3Spectrum Health Medical Group, Dept. of Urology, Grand Rapids, United States of America,
4GenomeDx Biosciences, Biostatistics, Vancouver, Canada,
5GenomeDx Biosciences, Clinical Research, Vancouver, Canada,
6GenomeDx Biosciences, Clinical Research, Vancouver, Canada,
7University of Michigan, Michigan Medicine, Dept. of Pathology, Ann Arbor, United States of America,
8GenomeDx Biosciences, Vancouver, Canada,
9Michigan Urological Clinic, Dept. of Urology, Grand Rapids, United States of America,
10Comprehensive Urology, Dept. of Pathology, Royal Oak, United States of America,
11Comprehensive Urology, Dept. of Urology, Royal Oak, United States of America,
12Urology Associates of Grand Rapids P.C, Dept. of Urology, Grand Rapids, United States of America,
13IHA Urology, Dept. of Urology, Ypsilanti, United States of America,
14Michigan Institute of Urology, Dept. of Urology, Troy, United States of America,
15Wayne State University, Dept. of Urology, Detroit, United States of America

Aims and objectives of this presentation

Multi-scale tissue architecture analysis of prostate cancer biopsies: A new imaging tissue biomarker of biochemical recurrence?

By: Pukl M. 1, Carraro A. 2, Korbelic J. 2, Harisson A. 2, Zhaoyang C. 2, Palcic B. 2, Macaulay C. 2, Guillaud M. 2, Volavsek M. 3

1GH Celje, Dept. of Urology, Celje, Slovenia,
2British Columbia Cancer Research Centre, Dept. of Integrative Oncology, Vancouver, Canada,
3Faculty of Medicine, University of Ljubljana, Dept. of Pathology, Ljubljana, Slovenia
Aims and objectives of this presentation
644

Identifying the optimal definition for early biochemical recurrence after radical prostatectomy: A risk-stratified approach to optimize postoperative follow-up and the use of timely salvage therapies

By: Mazzone E., Gandaglia, G., Knipper, S., Graefen, M., Gallina, A., Tilki, D., Suardi, N., Bandini, M., Cucchiara, V., Stabile, A., Dell’Oglio, P., Fossati, N., Montorsi, F., Briganti, A.

IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, URI, Milan, Italy, University Hospital Hamburg-Eppendorf, Dept. of Urology, Martini Klinik, Hamburg, Germany

Aims and objectives of this presentation
645

Testosterone replacement therapy prevents disease progression in men undergoing radical prostatectomy

By: Towe M., Huynh L.M., El-Khatib F.M., Yafi F.A., Ahlering T.
University of California, Dept. of Urology, Irvine, Orange, United States of America

Aims and objectives of this presentation
646

Evaluating the impact of lead-time bias on the observed efficacy of early salvage radiation therapy in prostate cancer: A post-hoc analysis of the RTOG 9601 trial

Henry Ford Hospital, Vattikuti Urology Institute, Center for Outcomes Research, Analytics and Evaluation, Detroit, United States of America

Aims and objectives of this presentation
647

What is the best definition of biochemical response to salvage radiation therapy in prostate cancer patients treated for PSA rising after radical prostatectomy? Results from a multi-institutional series


IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, Mayo Clinic, Dept. of Urology, Rochester, MN, United States of America, Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, IRCCS Ospedale San Raffaele, Dept. of
Aims and objectives of this presentation

648

Impact of primary Gleason pattern on results of early salvage radiotherapy after radical prostatectomy

By: Preisser F.1, Pompe R.S.2, Chun F.K-H.1, Graefen M.3, Huland H.3, Tilki D.3

1University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, 2University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 3University Hospital Hamburg-Eppendorf, Martini-Klinik, Hamburg, Germany

Aims and objectives of this presentation

649

Rates and patterns of metastases in patients with node-negative prostate cancer at radical prostatectomy that experience PSA failure: Post-hoc analysis of RTOG 9601 trial data

By: Sood A., Keeley J., Arora S., Dalela D., Jeong W., Rogers C., Peabody J., Menon M., Abdollah F.

Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America

Aims and objectives of this presentation

650

There is no way to compensate for a non-timely use of salvage radiation therapy in men with recurrent prostate cancer after radical prostatectomy


1IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, 4IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, 5IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy, 6IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology; URI, Milan, Italy, 7University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, 8Charité University Hospital Berlin, Dept. of Radiation Oncology, Berlin,
Tumor control outcomes of salvage cryotherapy for radiorecurrent prostate cancer at median 12 years follow-up

By: Nair S.M.¹, Peters M.², Abed H.¹, Van Der Voort Van Zyp J.², Van Son M.², Chin J.L.¹
¹London Health Sciences Centre, Dept. of Urology, London, Canada, ²University Medical Center Utrecht, Dept. of Radiotherapy, Utrecht, The Netherlands

Aims and objectives of this presentation
651

Long-term functional and oncological outcomes of salvage cryosurgery for locally recurrent prostate cancer following radiotherapy: A 12-year single center analysis

By: Exterkate L., Somford D.M., Vergunst H.
Canisius-Wilhelmina Hospital, Dept. of Urology, Nijmegen, The Netherlands

Aims and objectives of this presentation
652

Salvage cryotherapy versus salvage radical prostatectomy for radiorecurrent prostate cancer: Long-term oncologic outcomes

By: Nair S.M.¹, Lyon T.², Dewar M.¹, Rangel L.³, Abed H.¹, Hetou K.¹, Karnes R.², Chin J.¹, Boorjian S.²
¹London Health Sciences Centre, Division of Urology, London, Canada, ²Mayo Clinic, Division of Urology, Rochester, United States of America, ³Mayo Clinic, Dept. of Health Sciences Research, Rochester, United States of America

Aims and objectives of this presentation
653

Outcomes of the miltuximab first in human trial and proposed study design for a phase 1 trial 89zr/177lu theranostic trial

By: Campbell D.¹, Sabanathan D.², Gurney H.², Gillatt D.², Trifunovic M.³, Poursoltan P.⁴, Ho Shon K.³, Mackay T.¹, Roach P.⁵, Bailey D.⁵, Walsh B.¹
¹Minomic International Ltd, Macquarie Park, Australia, ²Macquarie University, Faculty of Medicine and Health Sciences, Macquarie Park, Australia, ³Macquarie Medical Imaging, Macquarie Park, Australia, ⁴Macquarie University, Faculty of Medicine and Health...
Aims and objectives of this presentation
655

656 PSA persistence after radical prostatectomy and its impact on oncologic outcomes
By: Preisser F. 1, Pompe R.S. 2, Chun F. 1, Graefen M. 3, Huland H. 3, Tilki D. 3
1University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, 2University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 3University Hospital Hamburg-Eppendorf, Martini-Klinik, Hamburg, Germany

Aims and objectives of this presentation
656

15:19 - 15:30 State-of-the-art lecture What are the current indications for salvage radiotherapy
G. De Meerleer, Ghent (BE)